Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Accumulated Expenses: 2013-2025

Historic Other Accumulated Expenses for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $1.3 million.

  • Theravance Biopharma's Other Accumulated Expenses rose 10.33% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 10.33%. This contributed to the annual value of $2.2 million for FY2024, which is 78.40% up from last year.
  • Latest data reveals that Theravance Biopharma reported Other Accumulated Expenses of $1.3 million as of Q3 2025, which was down 28.42% from $1.9 million recorded in Q2 2025.
  • Theravance Biopharma's Other Accumulated Expenses' 5-year high stood at $2.3 million during Q2 2022, with a 5-year trough of $142,000 in Q3 2022.
  • For the 3-year period, Theravance Biopharma's Other Accumulated Expenses averaged around $1.5 million, with its median value being $1.4 million (2023).
  • As far as peak fluctuations go, Theravance Biopharma's Other Accumulated Expenses crashed by 92.24% in 2022, and later spiked by 963.38% in 2023.
  • Theravance Biopharma's Other Accumulated Expenses (Quarterly) stood at $1.3 million in 2021, then declined by 12.42% to $1.1 million in 2022, then climbed by 8.67% to $1.2 million in 2023, then surged by 78.40% to $2.2 million in 2024, then grew by 10.33% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.9 million for Q2 2025, and $2.1 million during Q1 2025.